ReNerve Unveils Empliq Range, Targets Growth in Nerve Repair and Wound Care
ReNerve Ltd has launched its Empliq product range, marking its entry into the dermal and amniotic tissue repair markets with first sales already recorded and a US launch planned.
- Launch of Empliq product range including deep-layer dermal matrix and amniotic & placental allografts
- First sales achieved with market approval secured
- Partnership with Berkeley Biologics for scalable, compliant US production
- Upcoming launch at American Society Surgery of the Hand Annual Meeting in October 2025
- Expansion of revenue opportunities leveraging existing sales and distribution channels
Expanding Horizons in Nerve Repair
ReNerve Ltd, an ASX-listed medical device company, has taken a significant step forward in its growth strategy with the launch of the Empliq product range. This new portfolio includes deep-layer dermal matrices and amniotic and placental allografts designed to complement its existing nerve repair offerings. The Empliq products have already received market approval and recorded their first sales, signaling early commercial traction.
The Empliq range targets surgeons who routinely use dermal and amniotic membranes not only in nerve repair but also in broader wound care applications. By expanding into these adjacent markets, ReNerve aims to diversify its revenue streams while leveraging its established sales and distribution networks.
Strategic Partnership and Production Scale
Central to ReNerve’s launch is its partnership with Berkeley Biologics, a multi-service tissue bank known for high-quality allograft supply across orthopaedics, trauma, dental, and wound care sectors. This collaboration ensures that production can be efficiently scaled to meet anticipated demand while maintaining compliance with stringent US regulations for human cellular and tissue-based products.
Berkeley Biologics’ inventory management and regulatory expertise provide ReNerve with a robust platform to support its US market entry, which is scheduled to be formally introduced at the American Society Surgery of the Hand (ASSH) Annual Meeting in October 2025. This event is a strategic choice, offering direct access to key opinion leaders and potential customers in the surgical community.
Innovative Product Features
The Empliq product portfolio includes several specialized allografts, Empliq AmnioLite and AmnioDuo, which are single- and double-layer amniotic membrane allografts respectively; Empliq Placental, combining amniotic membrane and chorion; and Empliq Dermal, a deep-layer dermal matrix designed for soft tissue repair. Notably, the Empliq Dermal product is processed to remove the basement membrane, enhancing fluid management and accelerating tissue regeneration compared to competitor products.
These products are designed to provide natural barriers and scaffolds that support rapid, non-pathologic healing, particularly in chronic wound care scenarios such as diabetic foot ulcers and venous leg ulcers. Their room temperature storage and low inflammatory response further enhance their clinical appeal.
Market Potential and Next Steps
The global dermal and amniotic tissue repair markets are poised for growth, and ReNerve’s entry with the Empliq range positions the company to capitalize on this trend. While the company has not disclosed detailed sales figures or financial guidance, the initial market approval and first sales are promising indicators.
Investors and industry watchers will be keen to monitor how the Empliq products perform post-launch, particularly in the US market, and how effectively ReNerve can scale production and distribution through its Berkeley Biologics partnership. The upcoming ASSH Annual Meeting will be a critical milestone for gauging market reception and forging further clinical relationships.
Bottom Line?
ReNerve’s Empliq launch opens new revenue avenues but market adoption and scale remain key to watch.
Questions in the middle?
- How quickly will Empliq products gain traction among surgeons beyond initial sales?
- What are the competitive dynamics in the dermal and amniotic tissue repair markets?
- How will the Berkeley Biologics partnership impact ReNerve’s production capacity and regulatory compliance long term?
